Why does survival of hepatocellular carcinoma patients remain so low? Key stumbling blocks and questions in preclinical and clinical development

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address: [email protected]; European association for the study of the liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; Jul 69 (1): 182–236. Epub 2018 Apr 5. Erratum in: J Hepatol. 2019 Apr; 70(4):817. PMID: 29628281
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018Mar24;391(10126):1163–1173. PMID: 29433850.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. IMbrave150 investigators. atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020May14;382(20):1894–1905. PMID: 32402160.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008Jul24;359(4):378–390. PMID: 18650514.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25–34. Epub 2008 Dec 16. PMID: 19095497.
   PubMed Web of Science ®Google Scholar
• Vogel A, Qin S, Kudo M, et al. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2021Aug6; Epub 2021 Jun 2. PMID: 3408711568 649–658
   PubMed Web of Science ®Google Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022 Jan;23(1):77–90. Epub 2021 Dec 13. PMID: 34914889.
   PubMed Web of Science ®Google Scholar
• Yang J, Yan J, Targeting LB. VEGF/VEGFR to modulate antitumor immunity. Front Immunol. 2018; May3 9 978. PMID: 29774034; PMCID: PMC5943566
   PubMed Web of Science ®Google Scholar
• Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; May 15(5): 325–340. Epub 2018 Mar 6. PMID: 29508855; PMCID: PMC5921900
   PubMed Web of Science ®Google Scholar
• Lee WS, Yang H, Chon HJ, et al. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020; Sep 52 (9):1475–1485. Epub 2020 Sep 11. PMID: 32913278; PMCID: PMC8080646
   PubMed Web of Science ®Google Scholar
• IMbrave150. Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). Abs 267 2021 Gastrointestinal Cancers Symposium .
   Google Scholar
• Kelley RK, Yau T, Cheng AL, et al. VP10-2021: cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): results from the randomized phase III COSMIC-312 trial. Published:November 20, 2021.
   Google Scholar
• Abou-Alfa G, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Presented at: 2022 Gastrointestinal Cancers Symposium; 2022 Jan 20-22; San Francisco, California. Abstract 379.
   Google Scholar
• Bruix J, Qin S, Merle P, et al. RESORCE investigators. regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; Jan 7 389 (10064): 56–66. Epub 2016 Dec 6. Erratum in: Lancet. 36. PMID: 27932229
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016 Apr 14;2:16018. PMID: 27158749.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018Jul5; PMID: 29972759; PMCID: PMC75232443791 54–63
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang YK, Yen CJ, et al. REACH-2 study investigators. ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282–296. Epub 2019 Jan 18. PMID: 30665869.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet. 2017; Jun 24 389(10088): 2492–2502. Epub 2017 Apr 20. PMID: 28434648; PMCID: PMC7539326
   PubMed Web of Science ®Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. KEYNOTE-224 investigators. pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; Jul 19 (7): 940–952 Epub 2018 Jun 3. Erratum in: Lancet Oncol. 2018 Sep; 19(9):e440.PMID: 29875066
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo BY, Merle P, et al. KEYNOTE-240 investigators. pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in keynote-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020Jan20; Epub 2019 Dec 2. PMID: 31790344383 193–202
   PubMed Web of Science ®Google Scholar
• Rimini M, Shimose S, Lonardi S, et al. Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: a multi-institutional matched case-control study. Hepatol Res. 2021 Dec;51(12):1229–1241. Epub 2021 Oct 21. PMID: 34591334.
   PubMed Web of Science ®Google Scholar
• Burgio V, Iavarone M, Di Costanzo GG, et al. Real-life clinical data of lenvatinib versus sorafenib for unresectable hepatocellular Carcinoma in Italy. Cancer Manag Res. PMID: 34992463; PMCID: PMC8713715. 2021;Dec24 13:9379–9389.
   PubMed Web of Science ®Google Scholar
• Park R, Lopes da Silva L, Nissaisorakarn V, et al. Comparison of efficacy of systemic therapies in advanced hepatocellular carcinoma: updated systematic review and frequentist network meta-analysis of randomized controlled trials. J Hepatocell Carcinoma. PMID: 33791250; PMCID: PMC7997949. 2021;Mar22 8:145–154.
   PubMed Web of Science ®Google Scholar
• Sonbol MB, Riaz IB, Naqvi SAA, et al. Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.JAMA Oncol. 2020; Dec 1 6(12): e204930. Epub 2020 Dec 10. PMID: 33090186; PMCID: PMC7582230
   PubMed Web of Science ®Google Scholar
• Casadei-Gardini A, Tada T, Shimose S, et al. Is atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma superior even to lenvatinib? A matching-adjusted indirect comparison. Target Oncol. 2021 Mar;16(2):249–254. Epub 2021 Feb 27. PMID: 33638735.
   PubMed Web of Science ®Google Scholar
• Casadei-Gardini A, Rimassa L, Rimini M, et al. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. J Cancer Res Clin Oncol. 2021 Dec;147(12):3665–3671. Epub 2021 Mar 20. PMID: 33745079.
   PubMed Web of Science ®Google Scholar
• Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021; Apr 592(7854): 450–456. Epub 2021 Mar 24. PMID: 33762733; PMCID: PMC8046670
   PubMed Web of Science ®Google Scholar
• Rimini M, Kudo M, Tada T, et al. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open. 2021; Dec6(6): 100330. Epub 2021 Nov 27. PMID: 34847382; PMCID: PMC8710492 6
   PubMed Web of Science ®Google Scholar
• Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021 May;18(5):293–313. Epub 2021 Jan 28. PMID: 33510460.
   PubMed Web of Science ®Google Scholar
• Peck-Radosavljevic M, Kudo M, Raoul JL, et al. Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): global OPTIMIS final analysis. J Clin Oncol. 2018;36(15_suppl):4018.
   Web of Science ®Google Scholar
• Kudo M, Ueshima K, Chan S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and child-pugh a liver function: a proof-of-concept study. Cancers (Basel). 2019Jul31;11(8):1084. PMID: 31370183; PMCID: PMC6721438.
   PubMed Web of Science ®Google Scholar
• Casadei-Gardini A, Scartozzi M, Tada T, et al. Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: an inverse probability of treatment weighting analysis. Liver Int. 2021 Jun;41(6):1389–1397.
   PubMed Web of Science ®Google Scholar
• Pinter M, Ulbrich G, Sieghart W, et al. Hepatocellular carcinoma: a phase II randomized controlled double-blind trial of transarterial chemoembolization in combination with biweekly intravenous administration of bevacizumab or a placebo. Radiology. 2015;277(3):903–912.
   PubMed Web of Science ®Google Scholar
• Smolka S, Chapiro J, Manzano W, et al. The impact of antiangiogenic therapy combined with transarterial chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma. Clin Imaging. 2017; Nov-Dec 46 1–7. Epub 2017 Jun 7. PMID: 28668723; PMCID: PMC5720941
   PubMed Web of Science ®Google Scholar
• Meyer T, Fox R, Ting MY, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. The Lancet Gastroenterology & Hepatology. 2017;2(8):565–575.
   PubMed Web of Science ®Google Scholar
• Lencioni R, JM L, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. Journal of Hepatology. 2016;64(5):1090–1098.
   PubMed Web of Science ®Google Scholar
• Kudo M, Han G, FinnRS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology. 2014;60(5):1697–1707.
   PubMed Web of Science ®Google Scholar
• Kudo M, Cheng AL, Park JW, et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo controlled, multicentre, phase 3 study. Lancet Gastroenterol. Hepatol. 2018;3:37–46.
   Web of Science ®Google Scholar
• Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. European Journal of Cancer. 2011;47(14):2117–2127.
   PubMed Web of Science ®Google Scholar
• Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2019;69(8):1492–1501.
   PubMed Web of Science ®Google Scholar
• Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: a phase 3, multicenter, randomized controlled trial. Presented at ASCO GI 2022; January 20-22, 2022. Abstract 380.
   Google Scholar
• Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–1251.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer J, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5(10):1411–1420.
   PubMed Web of Science ®Google Scholar
• Sutherland LM, Williams JAR, Padbury RTA, et al. Radiofrequency ablation of liver tumors: a systematic review. Archives of Surgery. 2006;141(2):181–190.
   PubMedGoogle Scholar
• Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017; Mar 66 (3):545–551. Epub 2016 Nov 2. PMID: 27816492; PMCID: PMC5316490
   PubMed Web of Science ®Google Scholar
• Abeshouse A, Adebamowo C, Adebamowo SN, Cancer Genome Atlas Research Network. Electronic address edsc, cancer genome Atlas research N. comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171(4):950–65e28.
   PubMed Web of Science ®Google Scholar
• Schulze K, Imbeaud S, Letouze E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47(5):505–511.
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009;69(18):7385–7392.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Villanueva A, Lachenmayer A, et al. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12(8):436.
   PubMedGoogle Scholar
• Boyault S, Rickman DS, de Reyniès A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 2007Jan;451:42–52. PMID: 17187432
   PubMed Web of Science ®Google Scholar
• Kurebayashi Y, Ojima H, Tsujikawa H, et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018;68(3):1025–1041.
   PubMed Web of Science ®Google Scholar
• Fujita M, Yamaguchi R, Hasegawa T, et al. Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. EBioMedicine. 2020;53:102659.
   PubMed Web of Science ®Google Scholar
• Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology. 2017 Sep;153(3):812–826. Epub 2017 Jun 15. PMID: 28624577.
   PubMed Web of Science ®Google Scholar
• Shimada S, Mogushi K, Akiyama Y, et al. Comprehensive molecular and immunological characterization of hepatocellular carcinoma. EBioMedicine. 2019; Feb 40 457–470. Epub 2018 Dec 29. PMID: 30598371; PMCID: PMC6412165
   PubMed Web of Science ®Google Scholar